
ENGROSSED SUBSTITUTE HOUSE BILL 2034

State of Washington

57th Legislature

2001 Regular Session

By House Committee on Health Care (originally sponsored by Representatives Campbell, Hankins, O'Brien, Kagi, Reardon, Lambert, Boldt, Schoesler, Linville, Van Luven, Morris, Mastin, Murray, Santos, Talcott, Grant, Morell, Lisk, Dickerson, Carrell, Quall, Delvin, Miloscia, Conway, Buck, Kenney, Esser, Mulliken, G. Chandler, Bush, Ruderman, Benson, Haigh, Rockefeller, McDermott, Tokuda, Lovick, B. Chandler, Voloria, Dunn, Casada, Mielke, Pearson, Roach, Cooper, Simpson, Jackley, Ogden, Kessler, Anderson, DeBolt, Crouse, Pennington, Mitchell, Cairnes, D. Schmidt, Ericksen, Barlean, Pflug, Ahern, Cox, Hatfield, Doumit, Dunshee, Eickmeyer, Keiser, Poulsen, Gombosky, Romero, Fisher, Kirby and Hurst)

Read first time 02/22/2001. Referred to Committee on .

1 AN ACT Relating to authorizing optometrists to use and prescribe
2 approved drugs for diagnostic or therapeutic purposes without
3 limitation upon the methods of delivery in the practice of optometry;
4 and amending RCW 18.53.010, 18.53.140, 69.41.030, and 69.50.101.

5 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF WASHINGTON:

6 **Sec. 1.** RCW 18.53.010 and 1989 c 36 s 1 are each amended to read
7 as follows:

8 (1) The practice of optometry is defined as the examination of the
9 human eye, the examination and ascertaining any defects of the human
10 vision system and the analysis of the process of vision. The practice
11 of optometry may include, but not necessarily be limited to, the
12 following:

13 (a) The employment of any objective or subjective means or method,
14 including the use of drugs (~~topically applied to the eye~~),
15 diagnostic and therapeutic purposes by those licensed under this
16 chapter and who meet the requirements of subsections (2) and (3) of
17 this section, and the use of any diagnostic instruments or devices for
18 the examination or analysis of the human vision system, the measurement

1 of the powers or range of human vision, or the determination of the
2 refractive powers of the human eye or its functions in general; and

3 (b) The prescription and fitting of lenses, prisms, therapeutic or
4 refractive contact lenses and the adaption or adjustment of frames and
5 lenses used in connection therewith; and

6 (c) The prescription and provision of visual therapy, therapeutic
7 aids, and other optical devices (~~(, and the treatment with topically~~
8 ~~applied drugs by those licensed under this chapter and who meet the~~
9 ~~requirements of subsections (2) and (3) of this section)); and~~

10 (d) The ascertainment of the perceptive, neural, muscular, or
11 pathological condition of the visual system; and

12 (e) The adaptation of prosthetic eyes.

13 (2)(a) Those persons using drugs for diagnostic purposes in the
14 practice of optometry shall have a minimum of sixty hours of didactic
15 and supervised clinical instruction in general and ocular pharmacology
16 as applied to optometry, (~~and for therapeutic purposes, an additional~~
17 ~~minimum of seventy-five hours of didactic and clinical instruction)) as
18 established by the board, and certification from an institution of
19 higher learning, accredited by those agencies recognized by the United
20 States office of education or the council on postsecondary
21 accreditation to qualify for certification by the optometry board of
22 Washington to use drugs for diagnostic and therapeutic purposes.~~

23 (b) Those persons using or prescribing topical drugs for
24 therapeutic purposes in the practice of optometry shall be certified
25 under (a) of this subsection, and shall have an additional minimum of
26 seventy-five hours of didactic and supervised clinical instruction as
27 established by the board, and certification from an institution of
28 higher learning, accredited by those agencies recognized by the United
29 States office of education or the council on postsecondary
30 accreditation to qualify for certification by the optometry board of
31 Washington to use drugs for therapeutic purposes.

32 (c) Those persons using or prescribing drugs administered orally
33 for therapeutic purposes in the practice of optometry shall be
34 certified under (b) of this subsection, and shall have an additional
35 minimum of sixteen hours of didactic and eight hours of supervised
36 clinical instruction as established by the board, and certification
37 from an institution of higher learning, accredited by those agencies
38 recognized by the United States office of education or the council on
39 postsecondary accreditation to qualify for certification by the

1 optometry board of Washington to administer, dispense, or prescribe
2 oral drugs for therapeutic purposes.

3 (d) Those persons administering epinephrine by injection for
4 treatment of anaphylactic shock in the practice of optometry must be
5 certified under (b) of this subsection and must have an additional
6 minimum of four hours of didactic and supervised clinical instruction,
7 as established by the board, and certification from an institution of
8 higher learning, accredited by those agencies recognized by the United
9 States office of education or the council on postsecondary
10 accreditation to qualify for certification by the optometry board to
11 administer epinephrine by injection.

12 (e) Such course or courses shall be the fiscal responsibility of
13 the participating and attending optometrist.

14 (3) The board shall establish a schedule of drugs for diagnostic
15 and treatment purposes limited to the practice of optometry, and no
16 person licensed pursuant to this chapter shall prescribe, dispense,
17 purchase, possess, or administer drugs except as authorized and to the
18 extent permitted by the board.

19 (4) The board shall establish a list of legend drugs and Schedule
20 III through V controlled substances, in consultation and with the
21 approval of the board of pharmacy, and no person licensed under this
22 chapter shall prescribe, dispense, purchase, possess, or administer
23 these drugs except as authorized and to the extent permitted by the
24 board.

25 (a) The board, in consultation and with the approval of the board
26 of pharmacy, shall establish, by rule, specific guidelines for the
27 prescription and administration of drugs by optometrists, so that
28 licensed optometrists and persons filling their prescriptions have a
29 clear understanding of which drugs and which dosages or forms are
30 included in the authority granted by this section.

31 (b) No optometrist shall prescribe, dispense, or administer a
32 controlled substance for more than seven days in treating a particular
33 patient for a single trauma, episode, or condition.

34 (c) No optometrist may prescribe, dispense, or administer a
35 controlled substance for treating pain associated with an operative
36 procedure during ninety days of postoperative care, unless in
37 consultation with the practitioner who performed the operative
38 procedure.

1 (d) The prescription or administration of drugs as authorized in
2 this section is specifically limited to those drugs appropriate to
3 treatment of diseases or conditions of the human eye and its associated
4 structure that are within the scope of practice of optometry. The
5 prescription or administration of drugs for any other purpose is not
6 authorized by this section.

7 (5) The board shall develop a means of identification and
8 verification of optometrists certified to use therapeutic drugs for the
9 purpose of issuing prescriptions as authorized by this section.

10 (6) Nothing in this chapter shall be construed to authorize:
11 Administration of a drug by injection, except epinephrine for treatment
12 of anaphylactic shock; retinal repair surgery, eximer laser, or laser
13 in situ keratomileusis surgery; or the use, prescription, dispensing,
14 purchase, possession, or administration of any Schedule I and II
15 controlled substances. The provisions of this section shall be
16 strictly construed.

17 **Sec. 2.** RCW 18.53.140 and 1991 c 3 s 138 are each amended to read
18 as follows:

19 It shall be unlawful for any person:

20 (1) To sell or barter, or offer to sell or barter any license
21 issued by the secretary; or

22 (2) To purchase or procure by barter any license with the intent to
23 use the same as evidence of the holder's qualification to practice
24 optometry; or

25 (3) To alter with fraudulent intent in any material regard such
26 license; or

27 (4) To use or attempt to use any such license which has been
28 purchased, fraudulently issued, counterfeited or materially altered as
29 a valid license; or

30 (5) To practice optometry under a false or assumed name, or as a
31 representative or agent of any person, firm or corporation with which
32 the licensee has no connection: PROVIDED, Nothing in this chapter nor
33 in the optometry law shall make it unlawful for any lawfully licensed
34 optometrist or association of lawfully licensed optometrists to
35 practice optometry under the name of any lawfully licensed optometrist
36 who may transfer by inheritance or otherwise the right to use such
37 name; or

1 (6) To practice optometry in this state either for him or herself
2 or any other individual, corporation, partnership, group, public or
3 private entity, or any member of the licensed healing arts without
4 having at the time of so doing a valid license issued by the secretary
5 of health; or

6 (7) To in any manner barter or give away as premiums either on his
7 own account or as agent or representative for any other purpose, firm
8 or corporation, any eyeglasses, spectacles, lenses or frames; or

9 (8) To use drugs in the practice of optometry, except ((those
10 ~~topically applied for diagnostic or therapeutic purposes~~)) as
11 authorized under RCW 18.53.010; or

12 (9) To use advertising whether printed, radio, display, or of any
13 other nature, which is misleading or inaccurate in any material
14 particular, nor shall any such person in any way misrepresent any goods
15 or services (including but without limitation, its use, trademark,
16 grade, quality, size, origin, substance, character, nature, finish,
17 material, content, or preparation) or credit terms, values, policies,
18 services, or the nature or form of the business conducted; or

19 (10) To advertise the "free examination of eyes," "free
20 consultation," "consultation without obligation," "free advice," or any
21 words or phrases of similar import which convey the impression to the
22 public that eyes are examined free or of a character tending to deceive
23 or mislead the public, or in the nature of "bait advertising;" or

24 (11) To use an advertisement of a frame or mounting which is not
25 truthful in describing the frame or mounting and all its component
26 parts. Or advertise a frame or mounting at a price, unless it shall be
27 depicted in the advertisement without lenses inserted, and in addition
28 the advertisement must contain a statement immediately following, or
29 adjacent to the advertised price, that the price is for frame or
30 mounting only, and does not include lenses, eye examination and
31 professional services, which statement shall appear in type as large as
32 that used for the price, or advertise lenses or complete glasses, viz.:
33 frame or mounting with lenses included, at a price either alone or in
34 conjunction with professional services; or

35 (12) To use advertising, whether printed, radio, display, or of any
36 other nature, which inaccurately lays claim to a policy or continuing
37 practice of generally underselling competitors; or

38 (13) To use advertising, whether printed, radio, display or of any
39 other nature which refers inaccurately in any material particular to

1 any competitors or their goods, prices, values, credit terms, policies
2 or services; or

3 (14) To use advertising whether printed, radio, display, or of any
4 other nature, which states any definite amount of money as "down
5 payment" and any definite amount of money as a subsequent payment, be
6 it daily, weekly, monthly, or at the end of any period of time.

7 **Sec. 3.** RCW 69.41.030 and 1996 c 178 s 17 are each amended to read
8 as follows:

9 It shall be unlawful for any person to sell, deliver, or possess
10 any legend drug except upon the order or prescription of a physician
11 under chapter 18.71 RCW, an osteopathic physician and surgeon under
12 chapter 18.57 RCW, an optometrist licensed under chapter 18.53 RCW who
13 is certified by the optometry board under RCW 18.53.010, a dentist
14 under chapter 18.32 RCW, a podiatric physician and surgeon under
15 chapter 18.22 RCW, a veterinarian under chapter 18.92 RCW, a
16 commissioned medical or dental officer in the United States armed
17 forces or public health service in the discharge of his or her official
18 duties, a duly licensed physician or dentist employed by the veterans
19 administration in the discharge of his or her official duties, a
20 registered nurse or advanced registered nurse practitioner under
21 chapter 18.79 RCW when authorized by the nursing care quality assurance
22 commission, an osteopathic physician assistant under chapter 18.57A RCW
23 when authorized by the board of osteopathic medicine and surgery, a
24 physician assistant under chapter 18.71A RCW when authorized by the
25 medical quality assurance commission, a physician licensed to practice
26 medicine and surgery or a physician licensed to practice osteopathic
27 medicine and surgery, a dentist licensed to practice dentistry, a
28 podiatric physician and surgeon licensed to practice podiatric medicine
29 and surgery, or a veterinarian licensed to practice veterinary
30 medicine, in any province of Canada which shares a common border with
31 the state of Washington or in any state of the United States:
32 PROVIDED, HOWEVER, That the above provisions shall not apply to sale,
33 delivery, or possession by drug wholesalers or drug manufacturers, or
34 their agents or employees, or to any practitioner acting within the
35 scope of his or her license, or to a common or contract carrier or
36 warehouseman, or any employee thereof, whose possession of any legend
37 drug is in the usual course of business or employment: PROVIDED
38 FURTHER, That nothing in this chapter or chapter 18.64 RCW shall

1 prevent a family planning clinic that is under contract with the
2 department of social and health services from selling, delivering,
3 possessing, and dispensing commercially prepackaged oral contraceptives
4 prescribed by authorized, licensed health care practitioners.

5 **Sec. 4.** RCW 69.50.101 and 1998 c 222 s 3 are each amended to read
6 as follows:

7 Unless the context clearly requires otherwise, definitions of terms
8 shall be as indicated where used in this chapter:

9 (a) "Administer" means to apply a controlled substance, whether by
10 injection, inhalation, ingestion, or any other means, directly to the
11 body of a patient or research subject by:

12 (1) a practitioner authorized to prescribe (or, by the
13 practitioner's authorized agent); or

14 (2) the patient or research subject at the direction and in the
15 presence of the practitioner.

16 (b) "Agent" means an authorized person who acts on behalf of or at
17 the direction of a manufacturer, distributor, or dispenser. It does
18 not include a common or contract carrier, public warehouseperson, or
19 employee of the carrier or warehouseperson.

20 (c) "Board" means the state board of pharmacy.

21 (d) "Controlled substance" means a drug, substance, or immediate
22 precursor included in Schedules I through V as set forth in federal or
23 state laws, or federal or board rules.

24 (e)(1) "Controlled substance analog" means a substance the chemical
25 structure of which is substantially similar to the chemical structure
26 of a controlled substance in Schedule I or II and:

27 (i) that has a stimulant, depressant, or hallucinogenic effect on
28 the central nervous system substantially similar to the stimulant,
29 depressant, or hallucinogenic effect on the central nervous system of
30 a controlled substance included in Schedule I or II; or

31 (ii) with respect to a particular individual, that the individual
32 represents or intends to have a stimulant, depressant, or
33 hallucinogenic effect on the central nervous system substantially
34 similar to the stimulant, depressant, or hallucinogenic effect on the
35 central nervous system of a controlled substance included in Schedule
36 I or II.

37 (2) The term does not include:

38 (i) a controlled substance;

1 (ii) a substance for which there is an approved new drug
2 application;

3 (iii) a substance with respect to which an exemption is in effect
4 for investigational use by a particular person under Section 505 of the
5 federal Food, Drug and Cosmetic Act, 21 U.S.C. Sec. 355, to the extent
6 conduct with respect to the substance is pursuant to the exemption; or

7 (iv) any substance to the extent not intended for human consumption
8 before an exemption takes effect with respect to the substance.

9 (f) "Deliver" or "delivery," means the actual or constructive
10 transfer from one person to another of a substance, whether or not
11 there is an agency relationship.

12 (g) "Department" means the department of health.

13 (h) "Dispense" means the interpretation of a prescription or order
14 for a controlled substance and, pursuant to that prescription or order,
15 the proper selection, measuring, compounding, labeling, or packaging
16 necessary to prepare that prescription or order for delivery.

17 (i) "Dispenser" means a practitioner who dispenses.

18 (j) "Distribute" means to deliver other than by administering or
19 dispensing a controlled substance.

20 (k) "Distributor" means a person who distributes.

21 (l) "Drug" means (1) a controlled substance recognized as a drug in
22 the official United States pharmacopoeia/national formulary or the
23 official homeopathic pharmacopoeia of the United States, or any
24 supplement to them; (2) controlled substances intended for use in the
25 diagnosis, cure, mitigation, treatment, or prevention of disease in
26 individuals or animals; (3) controlled substances (other than food)
27 intended to affect the structure or any function of the body of
28 individuals or animals; and (4) controlled substances intended for use
29 as a component of any article specified in (1), (2), or (3) of this
30 subsection. The term does not include devices or their components,
31 parts, or accessories.

32 (m) "Drug enforcement administration" means the drug enforcement
33 administration in the United States Department of Justice, or its
34 successor agency.

35 (n) "Immediate precursor" means a substance:

36 (1) that the state board of pharmacy has found to be and by rule
37 designates as being the principal compound commonly used, or produced
38 primarily for use, in the manufacture of a controlled substance;

1 (2) that is an immediate chemical intermediary used or likely to be
2 used in the manufacture of a controlled substance; and

3 (3) the control of which is necessary to prevent, curtail, or limit
4 the manufacture of the controlled substance.

5 (o) "Isomer" means an optical isomer, but in RCW 69.50.101(r)(5),
6 69.50.204(a) (12) and (34), and 69.50.206(a)(4), the term includes any
7 geometrical isomer; in RCW 69.50.204(a) (8) and (42), and 69.50.210(c)
8 the term includes any positional isomer; and in RCW 69.50.204(a)(35),
9 69.50.204(c), and 69.50.208(a) the term includes any positional or
10 geometric isomer.

11 (p) "Manufacture" means the production, preparation, propagation,
12 compounding, conversion, or processing of a controlled substance,
13 either directly or indirectly or by extraction from substances of
14 natural origin, or independently by means of chemical synthesis, or by
15 a combination of extraction and chemical synthesis, and includes any
16 packaging or repackaging of the substance or labeling or relabeling of
17 its container. The term does not include the preparation, compounding,
18 packaging, repackaging, labeling, or relabeling of a controlled
19 substance:

20 (1) by a practitioner as an incident to the practitioner's
21 administering or dispensing of a controlled substance in the course of
22 the practitioner's professional practice; or

23 (2) by a practitioner, or by the practitioner's authorized agent
24 under the practitioner's supervision, for the purpose of, or as an
25 incident to, research, teaching, or chemical analysis and not for sale.

26 (q) "Marijuana" or "marihuana" means all parts of the plant
27 Cannabis, whether growing or not; the seeds thereof; the resin
28 extracted from any part of the plant; and every compound, manufacture,
29 salt, derivative, mixture, or preparation of the plant, its seeds or
30 resin. The term does not include the mature stalks of the plant, fiber
31 produced from the stalks, oil or cake made from the seeds of the plant,
32 any other compound, manufacture, salt, derivative, mixture, or
33 preparation of the mature stalks (except the resin extracted
34 therefrom), fiber, oil, or cake, or the sterilized seed of the plant
35 which is incapable of germination.

36 (r) "Narcotic drug" means any of the following, whether produced
37 directly or indirectly by extraction from substances of vegetable
38 origin, or independently by means of chemical synthesis, or by a
39 combination of extraction and chemical synthesis:

1 (1) Opium, opium derivative, and any derivative of opium or opium
2 derivative, including their salts, isomers, and salts of isomers,
3 whenever the existence of the salts, isomers, and salts of isomers is
4 possible within the specific chemical designation. The term does not
5 include the isoquinoline alkaloids of opium.

6 (2) Synthetic opiate and any derivative of synthetic opiate,
7 including their isomers, esters, ethers, salts, and salts of isomers,
8 esters, and ethers, whenever the existence of the isomers, esters,
9 ethers, and salts is possible within the specific chemical designation.

10 (3) Poppy straw and concentrate of poppy straw.

11 (4) Coca leaves, except coca leaves and extracts of coca leaves
12 from which cocaine, ecgonine, and derivatives or ecgonine or their
13 salts have been removed.

14 (5) Cocaine, or any salt, isomer, or salt of isomer thereof.

15 (6) Cocaine base.

16 (7) Ecgonine, or any derivative, salt, isomer, or salt of isomer
17 thereof.

18 (8) Any compound, mixture, or preparation containing any quantity
19 of any substance referred to in subparagraphs (1) through (7).

20 (s) "Opiate" means any substance having an addiction-forming or
21 addiction-sustaining liability similar to morphine or being capable of
22 conversion into a drug having addiction-forming or addiction-sustaining
23 liability. The term includes opium, substances derived from opium
24 (opium derivatives), and synthetic opiates. The term does not include,
25 unless specifically designated as controlled under RCW 69.50.201, the
26 dextrorotatory isomer of 3-methoxy-n-methylmorphinan and its salts
27 (dextromethorphan). The term includes the racemic and levorotatory
28 forms of dextromethorphan.

29 (t) "Opium poppy" means the plant of the species *Papaver somniferum*
30 L., except its seeds.

31 (u) "Person" means individual, corporation, business trust, estate,
32 trust, partnership, association, joint venture, government,
33 governmental subdivision or agency, or any other legal or commercial
34 entity.

35 (v) "Poppy straw" means all parts, except the seeds, of the opium
36 poppy, after mowing.

37 (w) "Practitioner" means:

38 (1) A physician under chapter 18.71 RCW, a physician assistant
39 under chapter 18.71A RCW, an osteopathic physician and surgeon under

1 chapter 18.57 RCW, an optometrist licensed under chapter 18.53 RCW who
2 is certified by the optometry board under RCW 18.53.010 subject to any
3 limitations in RCW 18.53.010, a dentist under chapter 18.32 RCW, a
4 podiatric physician and surgeon under chapter 18.22 RCW, a veterinarian
5 under chapter 18.92 RCW, a registered nurse, advanced registered nurse
6 practitioner, or licensed practical nurse under chapter 18.79 RCW, a
7 pharmacist under chapter 18.64 RCW or a scientific investigator under
8 this chapter, licensed, registered or otherwise permitted insofar as is
9 consistent with those licensing laws to distribute, dispense, conduct
10 research with respect to or administer a controlled substance in the
11 course of their professional practice or research in this state.

12 (2) A pharmacy, hospital or other institution licensed, registered,
13 or otherwise permitted to distribute, dispense, conduct research with
14 respect to or to administer a controlled substance in the course of
15 professional practice or research in this state.

16 (3) A physician licensed to practice medicine and surgery, a
17 physician licensed to practice osteopathic medicine and surgery, a
18 dentist licensed to practice dentistry, a podiatric physician and
19 surgeon licensed to practice podiatric medicine and surgery, or a
20 veterinarian licensed to practice veterinary medicine in any state of
21 the United States.

22 (x) "Prescription" means an order for controlled substances issued
23 by a practitioner duly authorized by law or rule in the state of
24 Washington to prescribe controlled substances within the scope of his
25 or her professional practice for a legitimate medical purpose.

26 (y) "Production" includes the manufacturing, planting, cultivating,
27 growing, or harvesting of a controlled substance.

28 (z) "Secretary" means the secretary of health or the secretary's
29 designee.

30 (aa) "State," unless the context otherwise requires, means a state
31 of the United States, the District of Columbia, the Commonwealth of
32 Puerto Rico, or a territory or insular possession subject to the
33 jurisdiction of the United States.

34 (bb) "Ultimate user" means an individual who lawfully possesses a
35 controlled substance for the individual's own use or for the use of a
36 member of the individual's household or for administering to an animal
37 owned by the individual or by a member of the individual's household.

38 (cc) "Electronic communication of prescription information" means
39 the communication of prescription information by computer, or the

1 transmission of an exact visual image of a prescription by facsimile,
2 or other electronic means for original prescription information or
3 prescription refill information for a Schedule III-V controlled
4 substance between an authorized practitioner and a pharmacy or the
5 transfer of prescription information for a controlled substance from
6 one pharmacy to another pharmacy.

7 NEW SECTION. **Sec. 5.** If any provision of this act or its
8 application to any person or circumstance is held invalid, the
9 remainder of the act or the application of the provision to other
10 persons or circumstances is not affected.

--- END ---